Supernus Pharmaceuticals and Indivior Merge to Create Specialized CNS Platform

Key Facts

1Supernus Pharmaceuticals is merging with Indivior to create a specialized CNS and addiction treatment platform.

2The combined entity targets $2.2B in revenue and $888M in adjusted EBITDA.

3Supernus growth products now comprise 80% of revenue, driven by sales growth of Qelbree and ZURZUVAE.

Supernus Pharmaceuticals is merging with Indivior to create a specialized platform for central nervous system (CNS) and addiction treatments. Seeking Alpha reported that Supernus shareholders voted to approve the merger agreement during a special meeting held on October 15, 2026. The combined entity targets $2.2 billion in revenue and $888 million in adjusted EBITDA.

Supernus growth products currently comprise 80% of its revenue, driven by sales of Qelbree and ZURZUVAE, as the company aims for $125 million in synergies from the deal. SUPN closed at $39.57 on October 15, 2026, having reached a day high of $41.31 during that session.